Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC
Authors
Keywords
Non–small cell lung cancer (NSCLC), TP53, KEAP1, Prognosis, Biomarkers
Journal
Journal of Thoracic Oncology
Volume 17, Issue 1, Pages 76-88
Publisher
Elsevier BV
Online
2021-10-01
DOI
10.1016/j.jtho.2021.08.764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
- (2020) Svenja Wagener-Ryczek et al. BMC CANCER
- Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
- (2020) Meiling Gong et al. Cell Communication and Signaling
- Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response
- (2020) Charu Aggarwal et al. CLINICAL CANCER RESEARCH
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of Population-Based Observational Studies With Randomized Trials in Oncology
- (2019) Payal D. Soni et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma
- (2019) Frauke Goeman et al. Journal of Thoracic Oncology
- Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients
- (2019) Youngtae Jeong et al. CLINICAL CANCER RESEARCH
- Molecular Testing for Early Lung Cancer
- (2018) Nasser K. Altorki ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Clinical and Pathological Characteristics ofKEAP1- andNFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
- (2018) Rieke Frank et al. CLINICAL CANCER RESEARCH
- A systematic review of p53 regulation of oxidative stress in skeletal muscle
- (2018) Kaitlyn Beyfuss et al. REDOX REPORT
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells
- (2018) Kamil Lisek et al. Oncotarget
- A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation
- (2018) Eran Kotler et al. MOLECULAR CELL
- Mutational processes shape the landscape of TP53 mutations in human cancer
- (2018) Andrew O. Giacomelli et al. NATURE GENETICS
- p53 Isoforms and Their Implications in Cancer
- (2018) Maximilian Vieler et al. Cancers
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- Mutant p53 as a target for cancer treatment
- (2017) Michael J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2017) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring?
- (2017) Roseanne McNamee STATISTICS IN MEDICINE
- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary
- (2017) Mark G. Kris et al. Journal of Oncology Practice
- ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology
- (2016) C. Heydt et al. ANNALS OF ONCOLOGY
- Targeting mutant p53 in cancer: a long road to precision therapy
- (2016) Fiamma Mantovani et al. FEBS Journal
- Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
- (2016) Xiaoli Ma et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Immunohistochemical correlates of TP53 somatic mutations in cancer
- (2016) Balázs Murnyák et al. Oncotarget
- TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
- (2016) Nitin H Shirole et al. eLife
- Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients
- (2015) Katharina König et al. Journal of Thoracic Oncology
- Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer
- (2014) M. A. Molina-Vila et al. CLINICAL CANCER RESEARCH
- A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitness
- (2014) Panagiotis Katsonis et al. GENOME RESEARCH
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Does Nrf2 Contribute to p53-Mediated Control of Cell Survival and Death?
- (2012) Weimin Chen et al. ANTIOXIDANTS & REDOX SIGNALING
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies
- (2012) Johannes R Kratz et al. LANCET
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Prognostic Significance of Truncating TP53 Mutations in Head and Neck Squamous Cell Carcinoma
- (2011) M. Lindenbergh-van der Plas et al. CLINICAL CANCER RESEARCH
- Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features
- (2010) L. M. Solis et al. CLINICAL CANCER RESEARCH
- Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer
- (2010) Tsuyoshi Takahashi et al. JOURNAL OF SURGICAL ONCOLOGY
- Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer
- (2010) Ana Belén Custodio et al. Journal of Thoracic Oncology
- The Isoforms of the p53 Protein
- (2009) M. P. Khoury et al. Cold Spring Harbor Perspectives in Biology
- Mutant p53 Gain-of-Function in Cancer
- (2009) M. Oren et al. Cold Spring Harbor Perspectives in Biology
- Clinical Outcomes and Correlates of TP53 Mutations and Cancer
- (2009) A. I. Robles et al. Cold Spring Harbor Perspectives in Biology
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started